Earlier quoted context omitted.
> difficult to trust the numbers coming from any country for a variety of reasons This must be a golden age for those doing a dissertation on media studies. So many quant-driven narratives, so little time. Hopefully cross-country data and narratives are being archived and aggregated into an open-data academic repository that can be studied in coming years.
Given that raw data of vaccine trials aren't even being made public I doubt that any reliable data is being collected, let alone analysed
https://www.reuters.com/business/healthcare-pharmaceuticals/...
> recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent infection by the Omicron variant ... the debate appears to have shifted with the European Medicines Agency (EMA) saying on Friday that international regulators now preferred clinical studies to be carried out before approval of a new vaccine ... it may not be possible to realise a current plan to launch an Omicron-targeting vaccine by the end of March ... Inclusion of clinical trial data in the regulatory filings may have an impact on the delivery of initial batches.